PROSTVAC™

Therapeutic vaccine candidate for the treatment of advanced prostate cancer.

Phase II

PROSTVAC™ is planned to enter Phase III clinical trials in late 2010

bluedot

PROSTVAC™ is a therapeutic vaccine candidate moving into late stage clinical development that has the potential to significantly extend the lives of men with advanced prostate cancer with improved quality of life.

The vaccine is administered subcutaneously and induces a specific, targeted immune response that attacks metastatic cells in the prostate. Conventional chemotherapy currently used to treat prostate cancer has limited survival rates and is often associated with numerous side effects.

In clinical trials to date PROSTVAC™ has been investigated in more than 500 patients.

  • 9 clinical studies have been completed and published
  • 2 Phase II studies have been completed
  • 5 clinical studies are ongoing

PROSTVAC™ characteristics

Extended median overall survival of 8.5 months compared to placebo (24 months versus 16 months)

Currently the only treatment (chemotherapy) with a survival benefit approved for advanced prostate cancer extends median overall survival by an average of approximately 2-3 months

Phase II study achieved a p-value of 0.006

Reduced the risk of death by 44% compared to placebo (HR=0.559)

Off-the-shelf vial vaccine that does not require complex individualised therapy

Recombinant viral vaccine that can be manufactured and reproduced easily. Other prostate cancer vaccine candidates are cell based and therefore difficult to scale, produce and standardize

Very favourable safety and tolerability profile

Holds the promise of moving into larger patient populations in earlier stages of the disease

More information

PROSTVAC website